Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 16.4%

Gross margin was 16.4% in Q1 FY2026, down 78.6 pp from a year earlier. On a trailing-twelve-month basis it was 99.3%, up 6.7 pp year over year. Over 3 fiscal years it widened by 8.5 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
16.4%-83.5 pp QoQ
Last fiscal yearDec 2025
99.4%+7.2 pp YoY
LTMMar 2026
99.3%+6.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-78.6 pp——
1 year+7.2 pp——
3 years+8.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.4%
Year-over-year change
+7.2pp

Gross Margin vs competitors

How OBIO compares with its peers on the latest reported figures

  • OBIO's LTM Mar 2026 gross margin of 99.3% is the 3rd highest of the 9 companies compared; the peer median is 94.8%.
  • Its year-over-year change of +6.7 pp is the 2nd highest of 7, against a peer median of -2.0 pp.
  • Over three fiscal years its change of +8.5 pp compares with a peer median of -6.7 pp.
OBIO Competitors Peer median
Gross Margin for OBIO and competitors
Company Period LTM level YoY 3-year change
TNYATenaya Therapeutics, Inc.LTM Mar 2026144.9% ——
PYXSPyxis Oncology, Inc.LTM Mar 202699.8% ——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202699.3% +6.7 pp+8.5 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
IVAInventiva S.A.FY202533.7% -66.3 pp-106.4 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-17996.6% -16820.4 pp+19.0 pp
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding OBIO) 94.8%-2.0 pp-6.7 pp

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.